Leonard E. Post - 04 Jun 2026 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Reporting relationship: Director
Issuer ticker: CGON
Reported as of: 04 Jun 2026
Net transaction value: -$54,500
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:30:07 UTC
Prior SEC filing: 18 Nov 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua Patterson, Attorney-in-Fact for Leonard Post

Key filing fact

Leonard E. Post filed Form 4 for CG Oncology, Inc. (CGON) on 05 Jun 2026.

Key facts

This page summarizes Leonard E. Post's Form 4 filing for CG Oncology, Inc. (CGON).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: -$54,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235862 Primary reporting owner

POST LEONARD E

Relationship: Director
Address: C/O CG ONCOLOGY, INC., 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS
Signature: /s/ Joshua Patterson, Attorney-in-Fact for Leonard Post
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CGON transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,000
Change %
Price: $0.6000^*
Shares after: 1,000
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

CGON transaction

Common Stock

Sale

Transaction value: $54,500
Shares: -1,000
Change %: -100%
Price: $54.50
Shares after: 0
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGON transaction Derivative

Director Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -1,000
Change %: -0.85%
Price: $0.000000^*
Shares after: 116,077
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000
Exercise price: $0.6000
Footnotes: F1, F2

CGON transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value
Shares: +9,354
Change %
Price: $0.000000^*
Shares after: 9,354
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,354
Exercise price: $56.09
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026

Footnote F2

Fully vested.

Footnote F3

1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.